Madrigal Pharmaceuticals is a biopharmaceutical company founded in 2016, focusing on developing therapeutics for metabolic and fatty liver diseases. The company's first therapy received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis and is currently undergoing a Phase 3 trial for the treatment of NASH with compensated cirrhosis. Madrigal Pharmaceuticals operates in the biopharma, biotechnology, medical devices, and pharmaceutical industries. The company's recent Post-IPO Equity investment on 18th March 2024 marks a significant milestone in its financial journey.
Madrigal Pharmaceuticals
Madrigal is focused on delivering novel therapeutics for MASH, a serious liver disease.
Founded 2016
Conshohocken, United States
1129 employees
IPO
Total: $1.68B
Biopharma, Biotechnology +2
Conshohocken, United States
1129 employees
IPO
Total: $1.68B
Biopharma, Biotechnology +2
General Information
Company Name
Madrigal Pharmaceuticals
Founded Year
2016
Location
Conshohocken, United States
Conshohocken, United States
Founders / Decision Makers
Employees
1129
Industries
Biopharma, Biotechnology, Medical Devices +1
Funding Stage
IPO
Social
BounceWatch is an independent company data service, not affiliated with Madrigal Pharmaceuticals. To contact Madrigal Pharmaceuticals, visit madrigalpharma.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Madrigal Pharmaceuticals compare?
A PDF of Madrigal Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Madrigal Pharmaceuticals soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Madrigal Pharmaceuticals on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biopharma
About Madrigal Pharmaceuticals
Business keywords: Biopharmaceutical, Therapeutics, Metabolic diseases, Liver disease, NASH treatment, Cardiovascular-metabolic diseases, Diabetes treatment, Dyslipidemia treatment, Clinical-stage biopharmaceutical company, Accelerated approval, Phase 3 trial, Nonalcoholic steatohepatitis, Compensated cirrhosis, Liver fibrosis, FDA approval
Funding Rounds & Investors (9)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $500.00M | 1 |
|
01 Jul 2025 |
| Post-IPO Equity | $90.00M | - |
|
01 Apr 2024 |
| Post-IPO Equity | $500.00M | - |
|
01 Sep 2023 |
| Post-IPO Debt | $259.00M | - |
|
01 Dec 2022 |
| Post-IPO Debt | $250.00M | 1 |
|
01 May 2022 |
| Private Placement VC | $35.00M | - |
|
01 Jul 2017 |
| IPO | $3.40M | - |
|
01 May 2016 |
| Convertible Note | $2.80M | 1 |
|
01 Jul 2015 |
| Convertible Note | $36.10M | 1 |
|
01 Sep 2011 |
Latest News
View All
Madrigal Pharmaceuticals Alternatives & Competitors
View All Alternatives
Madrigal Pharmaceuticals vs
GENFIT
France
Dedicated to improving the lives of patients with liver diseases characterized by high unmet medical...
Post-IPO Equity
201 employees
Biopharma, Biotechnology
Madrigal Pharmaceuticals vs
Pioneering the future of liver and metabolic disease treatment with innovative insulin sensitizers.
Series A
Biopharma, Biotechnology
Madrigal Pharmaceuticals vs
89bio
United States
Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic...
Post-IPO Equity
123 employees
Biopharma, Biotechnology
HighTide Therapeutics
FAQ About Madrigal Pharmaceuticals
Madrigal is focused on delivering novel therapeutics for MASH, a serious liver disease.
Madrigal Pharmaceuticals was founded in 2016.
Madrigal Pharmaceuticals is headquartered in Conshohocken, United States.
Madrigal Pharmaceuticals operates in Biopharma, Biotechnology, Medical Devices and Pharmaceutical. Its work centres on Biopharmaceutical, Therapeutics, Metabolic diseases and Liver disease.
Madrigal Pharmaceuticals has approximately 1129 employees.
Madrigal Pharmaceuticals has completed 9 funding rounds, raising a total of $1.68B. The latest funding stage is IPO.
Top alternatives and competitors to Madrigal Pharmaceuticals include GENFIT, Cirius Therapeutics, 89bio, Hepion Pharmaceuticals, Ocera Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Madrigal Pharmaceuticals and GENFIT are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Madrigal Pharmaceuticals, https://bouncewatch.com/company/madrigal-pharmaceuticals, updated 9 June 2026. When citing, please name BounceWatch and link this page.
